PERSPECTIVE THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $160.00K, a 10.34% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $290.00K.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $226.00K, a 64.80% decline year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $145.00K, a 13.28% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $371.00K, a 70.39% decline from fiscal 2024.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.25M, a 126.17% increase from fiscal 2023.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $554.00K.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $56.00K, a 89.51% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $160.00K 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $290.00K 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $371.00K 10-K · filed 2026-03-16 | |
| 2025-09-30 | $226.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $145.00K 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $1.25M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $642.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $128.00K 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $126.00K 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $554.00K 10-K/A · filed 2025-03-28 | |
| 2023-09-30 | $22.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $532.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $0.00 derived: 10-K 6 month − 10-Q 3 month · filed 2024-03-28 | |
| 2022-09-30 | $28.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $56.00K 10-K · filed 2024-03-28 | |
| 2021-12-31 | $56.00K 10-Q · filed 2022-05-13 | |
| 2021-06-30 | $534.00K 10-KT · filed 2023-05-01 | |
| 2021-03-31 | $288.00K 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $3.00K 10-Q · filed 2022-05-13 | |
| 2020-06-30 | $131.00K 10-KT · filed 2023-05-01 | |
| 2020-03-31 | $131.00K 10-Q · filed 2021-05-14 | |
| 2019-06-30 | $15.00K 10-K · filed 2021-09-27 | |
| 2019-03-31 | $2.00K 10-Q · filed 2020-05-13 | |
| 2018-06-30 | $50.00K 10-K · filed 2020-09-25 | |
| 2017-12-31 | $50.00K 10-Q · filed 2019-05-10 | |
| 2017-06-30 | $2.00K 10-K · filed 2019-09-27 | |
| 2016-06-30 | $50.00K 10-K · filed 2018-09-26 | |
| 2015-06-30 | $213.00K 10-K · filed 2017-09-28 | |
| 2014-06-30 | $266.31K 10-K · filed 2016-09-09 | |
| 2013-06-30 | $13.13K 10-K · filed 2015-09-14 | |
| 2012-06-30 | $5.10K 10-K · filed 2013-09-30 | |
| 2011-06-30 | $56.03K 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |